Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials How To Prevent Failure in Rare Disease Trials? Aligning Trials with Patient-Lived Experiences Beyond the Feasibility Survey: Strategic Site Selection to Accelerate Trials and Optimize Resources Conducting Rare Disease Clinical Trials to Support Market Access and Commercialization
Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials How To Prevent Failure in Rare Disease Trials? Aligning Trials with Patient-Lived Experiences Beyond the Feasibility Survey: Strategic Site Selection to Accelerate Trials and Optimize Resources Conducting Rare Disease Clinical Trials to Support Market Access and Commercialization
